Navigation Links
Vystar Corporation Announces Agreement with Kildare Capital to Provide Investment Banking Services
Date:6/30/2008

ATLANTA, June 30 /PRNewswire/ -- Vystar Corporation today announced that Kildare Capital, a registered broker-dealer near Philadelphia, will provide investment banking services for the company.

Vystar Corporation is the exclusive creator of the innovative technology to produce Vytex(TM) Natural Rubber Latex (NRL). This patented technology reduces antigenic protein in natural latex products to virtually undetectable levels. Latex allergy has become an increasing concern, particularly in the healthcare industry where workers have prolonged and/or repeated contact with latex. It is estimated that as many as 17 percent of healthcare workers and three percent of the general population could have an allergic reaction to the protein in natural rubber latex. Vytex NRL reduces the levels of such proteins while maintaining the superior product qualities, like barrier protection, strength and durability, fit and comfort, positive environmental impact, and cost, in the vast array of everyday products made with natural rubber latex.

According to William Doyle, Vystar's Chief Executive Officer, the agreement with Kildare Capital is an important step in Vystar's journey to becoming a publicly traded company, and in achieving its goal of making Vytex NRL the standard source of latex and latex substitutes. "It is virtually unprecedented that an organization with the stature of Kildare Capital would come on as an investment banker for Vystar in our pre-revenue phase and prior to an initial public listing. They were attracted to our great progress towards commercializing Vytex NRL and the excellent test results achieved to date."

In the past six months, Vystar:

-- Signed a definitive toll manufacturing agreement with Revertex Malaysia, the world's largest producer of prevulcanized natural rubber lattices and postvulcanized latex compounds as well as the sole producer of evaporated natural rubber lattices;

-- Was added to Universal Capital Management's portfolio of companies for management and strategic growth resources;

-- Contracted with a U.S. manufacturer of condoms and straight-dipped gloves to develop products manufactured with Vytex NRL and in turn complete the biocompatibility tests for 510(k) submission to the U.S. Food and Drug Administration;

-- Signed almost 20 sampling agreements and evaluations with major manufacturers in the exam and surgical glove, foam, medical device, and condom industries.

According to Sean Sweeney, President of Kildare Capital, his firm was also attracted to Vystar's large market potential and strong progress. "It is not often we run across a product like Vytex NRL that has the potential to fundamentally change such a large industry in a cost effective manner. We believe this represents an attractive opportunity for long-term growth potential."

About Kildare Capital:

Kildare Capital, founded in 2000, is a registered broker-dealer and FINRA/MSRB member firm providing investment banking, institutional trading and capital introduction services for institutional investors, corporate clients, venture capitalists, entrepreneurs and financial sponsors. With demonstrated public market private equity and hedge experience, the company specializes in underwriting niche capital requirements through follow-on offerings, municipal debt and venture/growth transactions.

About Vystar Corporation:

Vystar Corporation, incorporated in 2003, is a privately funded corporation located in the Atlanta area. It is included in the portfolio of Universal Capital Management, Inc. (OTC Bulletin Board: UCMT.OB), a business development company that provides management and strategic growth resources to emerging growth companies. The company's operations have been focused substantially on early-stage research, development, testing and commercialization of the Vytex NRL process. Vystar, named a 2007 Top 10 Innovative Technology Company in Georgia by the Technology Association of Georgia (TAG), holds two U.S. patents for the Vytex(TM) NRL technology, with two additional filings pending. For more information, please visit http://www.vytex.com .

Forward-looking Statements:

Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words, such as Vystar Corporation "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe Vystar's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Vystar as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Vystar believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Vystar does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.


'/>"/>
SOURCE Vystar Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Vystar Corporation and Revertex Malaysia Sign Vytex(TM) NRL Production Contract
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. Brooke Franchise Corporation Announces Selected July Results
4. MedThink Communications Retained by NanoBio Corporation
5. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
6. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
7. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
8. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
9. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
10. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
11. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys during ... wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy and ... exchange for generous donations, customers will receive a gift in return. Anyone who ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic ... redesigned website, which launched October 17, 2016, features comprehensive information regarding a wide ... layout. Visitors and patients can discover the latest clinical dermatology treatments for medical ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Campaign Winner in the Folio: Marketing Awards competition. Live From won in the ... in pioneering, inventive, and ultimately successful projects undertaken by the media industry’s most ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
(Date:12/7/2016)... ... , ... “Walking With God: Inspirational Lessons from My Life's Journey”: a ... aware of God's direction in their lives. “Walking With God: Inspirational Lessons from My ... church leader. , Sanford says, “I enjoy sharing the true stories in ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016 According to responses ... more than one-third (38%) of patients with non-small cell lung ... growth factor receptor (EGFR) genetic mutation status. The findings of ... LBA ID #6067 #P3.02b ) at the 2016 ... Austria . The survey results revealed an ...
(Date:12/7/2016)... Boehringer Ingelheim today announced that the ... malignant pleural mesothelioma (MPM) met its primary endpoint ... the 17 th IASLC World Conference on ... showed nintedanib plus pemetrexed/cisplatin demonstrated a meaningful clinical ... significantly improved PFS (9.4 vs 5.7 months). Preliminary ...
(Date:12/7/2016)... 7, 2016 Today, Stock-Callers.com presents four ... JAZZ ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ... AveXis Inc. (NASDAQ: AVXS ). From its peak ... 37% to reach a level equal to what it saw ... approximately 14% for the year, it has still out-performed other ...
Breaking Medicine Technology: